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Abstract
Objective to evaluate the perception of the maltese 
general public on generic medicinal products.
Method a self-administered questionnaire was 
compiled and distributed to a sample of the general public. 
data collected from the questionnaires was analysed using 
spss® version 19.
Key findings five hundred and forty four 
questionnaires were completed. fifty one percent of the 
respondents did not know the meaning of the term ‘generic 
medicinal product’ and 47% of the respondents became 
familiar with the term through the questionnaire.
Conclusion improved communication amongst 
patients and healthcare professionals on the correct 
meaning of generic medicinal products and their medical 
and financial implications is required.
Keywords public perception, generic medicinal 
product, originator medicinal product.
Introduction
a generic medicinal product is defined as that product which 
does not have patent protection or which is a chemically 
identical copy of an originator product whose patent has 
expired and can now be manufactured by any company 
interested in doing so. a generic medicinal product must 
also be bioequivalent to the originator product and must be 
produced within strict good manufacturing practice limits. 
article 10 paragraph 2 (b) of directive 2001/83/Ec defines a 
‘generic medicinal product’ as “a medicinal product which 
has the same qualitative and quantitative composition in 
active substances and the same pharmaceutical form as the 
reference medicinal product and whose bioequivalence with 
the reference medicinal product has been demonstrated by 
appropriate bioavailability studies.”1
use of generic products contributes to the sustainability 
of a cost-effective healthcare system where the generic 
medicinal product is not only cheaper and more affordable 
than the originator product; it also has the same indications 
and effects and is interchangeable with the originator 
product. the availability of generic medicines is playing a 
key role in healthcare and their importance in the developed 
world is steadily increasing.
prescribers in malta are not required by law to prescribe 
drugs by the international non-proprietary name (inn). 
on the 14th september 2006, the times of malta published 
an article entitled ‘proposal to ban prescription of brand 
medicines turned down’ which described the suggestion 
of an amendment to the medicines act, whereby doctors 
would be obliged by law to prescribe by the inn.2 this 
would allow greater exposure to generic medicines, which 
offer a cheaper alternative to their branded counterpart, 
as well as a greater acceptance thereof by the public since 
no substitution by the pharmacist needs to be undertaken. 
the patient would consequently, be getting exactly what is 
prescribed requiring no explanation with respect to product 
substitution. this suggestion was, however, turned down by 
the government, leaving doctors with the capacity to choose 
whether to prescribe by trade name. still, pharmacists can 
legally offer generic alternatives to medicines prescribed 
according to article 80 of the medicines act 2003 unless 
the doctor specifically indicates on the prescription that no 
substitution is allowed.3,4 
the struggle between originator and generic medicinal 
products is ongoing, with both sides constantly presenting 
their advantages and disadvantages. in this dispute 
however, one must not lose sight of who the ultimate 
winner or loser is: the patient. the aim of the study was to 
evaluate the perception of the maltese public on generic 
medicinal products.
Method
a self-administered questionnaire for the general public 
was developed for data collection. the questionnaire was 
validated in terms of layout, structure and content and 
tested for reliability through a pilot study.  a group of 19 
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individuals, including an English language teacher,  lawyer, 
financial advisor, two general practitioners, podiatrist, 
3 community pharmacists and 10 members of the 
general public were asked to complete the questionnaire 
twice within a two-week interval during the pilot study. 
amendments to the questionnaire were made and a final 
version of the questionnaire was developed. 
the questionnaire consisted of multiple choice close-ended 
questions and an open-ended question and was available 
in both English and maltese language. the questionnaire 
was divided into two sections: patient demographic data 
(age, occupation and level of education) and perception of 
generic medications. complete anonymity was ensured. 
the questionnaire was distributed via electronic mail with 
a covering letter to all available contacts of the researcher. 
the recipients were asked to fill in the questionnaire and 
forward it to all their own contacts. data collection was 
undertaken over a two-month period. 
the data collected was inputted into a specifically designed 
spreadsheet, filtered and then analysed using spss® version 
19. descriptive statistics were undertaken and p-values less 
than 0.05 were considered to be statistically significant. the 
association between the categorical variables in the study 
(knowledge of generics and swapping to a generic in an 
out of stock scenario; knowledge of generics and keeping 
the generic alternative as opposed to going back to the 
originator product) was assessed by the chi-square test for 
qualitative variables. since this type of analysis is inferring 
from a part (the sample) to a whole (the population), the 
margin of error was also calculated (for this sample size the 
margin of error is 4.2%), so that the safety of generalisation 
from said part to whole, could be quantified. the reliability 
of such a generalisation is also dependent on how well the 
sample is mirroring the whole population.5
Figure 1: information obtained about generic medicines (n=544)
Results
five hundred and seventy seven questionnaires were 
collected. however, 33 questionnaires were deemed to be 
invalid and were excluded from the study. the total sample 
size for the study was 544 participants.
fifty one percent of the participants did not know the 
meaning of the term generic medicinal product. for 
those participants who responded ‘no’ to the question 
‘do you know what the term generic medicines means?’, 
a brief description was given together with an example of 
ibuprofen, with nurofen® as the originator medicine and 
irfen® as the generic medicine. when asked ‘where did you 
first get to know about generic medicines?’ most of the 
participants (47%) responded that they became familiar 
with the term through the questionnaire (figure 1). 
although 51% of the respondents were not initially familiar 
with the term ‘generic medicines’, once a description and 
an example were provided, 58% of these respondents 
acknowledged using generic medicines in the past. 
when asked what they would do if a particular medication 
was out of stock, most of the consumers (59%) would 
immediately switch to the generic equivalent however 37% 
of the respondents would go round various community 
pharmacies to check whether any left-over stock is 
available. three percent of the respondents would prefer 
to remain with no medication until the originator is back 
in stock rather than switch to a generic. one percent of the 
respondents did not respond to this question. 
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when analysed statistically, a higher proportion of 
respondents who were familiar with the term ‘generic 
medicines’ would switch to a generic product immediately 
if the originator medicine is out of stock and conversely a 
higher proportion of those who were not familiar with the 
term would prefer to remain without any medication or go 
around several pharmacies to check for any left-over stock 
rather than switch to a generic medicine (p=0.000). most of 
the respondents (46%) would switch back to the originator 
product once it is back in stock (figure 2). 
when analysed statistically, there is an association between 
the knowledge of the term ‘generic medicines’ and whether 
the consumer would go back to the originator or keep 
taking the generic alternative.  results show that from the 
percentage of respondents who were familiar with the term 
‘generic medicines’ a higher proportion of respondents will 
keep taking the generic alternative even when the originator 
product is back in stock compared to the respondents  who 
were not familiar with the term (p=0.002).
Figure 2: practice when originator product is re-available (n=544)
Discussion
the knowledge of generic medicines amongst the maltese 
population compares favourably with a study carried out in 
Jamaica in 2006 where 64% of the respondents had either 
never heard of the term or were familiar with it but not sure 
what it meant.6 similarly, in studies carried out in germany 
in 2005 and in Japan in 2007 and 2008, 63% and 68% of 
consumers respectively were familiar with the term ‘generic 
medicines’.7,8
the healthcare professional has historically been 
unofficially entrusted with the role of educator when it 
comes to medicine and health. taking this into account, the 
public was asked a question with respect to their source of 
knowledge concerning generic medicines. the majority of 
respondents in this study learnt about generic medicines 
from the explanation provided in the questionnaire and 
whilst more respondents acquired knowledge of the term 
from healthcare professionals compared to the media, 
the difference is marginal. when asked what they would 
do if a particular medication was out of stock, most of the 
consumers in this study would immediately switch to the 
generic equivalent or would go round various community 
pharmacies to check whether any left-over stock is available. 
what is worrying is that a percentage of respondents, 
albeit a small one (3%) would rather stay without their 
medication until the originator is back in stock. how safe 
this is, is understandably debatable, and both latter figures 
may reflect the effects of a lack of knowledge of what 
generic medicines truly are. this can be further highlighted 
in the responses to the next question where most of the 
respondents in this study would revert back to the originator 
product when it is back in stock and not stick to the generic 
alternative. 
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Conclusion
in malta, the generics market is still in its infancy and as can 
be seen from the results obtained in the present study, the 
maltese population needs more awareness with respect to 
generic medicines. this can take the form of educational 
campaigns which seem to be lacking in this field. such 
campaigns may be targeted towards the public as well as 
healthcare professionals, who may then be better equipped 
and confident to educate their patients. the public 
awareness campaign may also include specific information 
to provide correct understanding by consumers of generic 
substitution. the perception of substandard medicines and 
generic medicines being interchangeable terms comes 
from a time before the 1996 world trade organisation 
agreement which provided the 20-year patent protection 
for pharmaceuticals. some argue that “the only consistent 
practical difference between generic and patented drugs is 
their price”.9
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